SNTI

Senti Biosciences Holdings, Inc. (SNTI) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Senti Biosciences is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform. The company completed a holding company reorganization on April 24, 2026. As of the reporting date, the company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Debt and Liquidity: In May 2026, the company issued $10.0 million in senior secured convertible notes to a related party (Celadon affiliate). As of June 30, 2026, the fair value of these notes was recorded at $4.0 million. The company holds $1.4 million in restricted cash, primarily for lease letters of credit.

Material Changes vs. Prior Period

• Reduced Net Loss: The net loss decreased by $11.9 million (41%) compared to the prior year period, primarily driven by a one-time $6.9 million gain on lease modification resulting from the restructuring of the Alameda facility lease.
• Operating Expenses: Research and Development (R&D) expenses decreased by $6.3 million to $13.0 million, largely due to reduced external services for the SENTI-202 program. General and Administrative (G&A) expenses decreased slightly by $0.9 million to $13.0 million.
• Sublease Income: GeneFab sublease income decreased by $2.2 million to $1.1 million due to the lease amendments reducing the subleased premises.
• Balance Sheet: Total assets decreased from $51.2 million to $33.1 million, reflecting a reduction in cash and lease-related assets following the lease modification and operating burn.

Outlook, Risks, and Unusual Items

• Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern. With $6.5 million in cash, the company may not be able to maintain operations starting as early as the fourth quarter of 2026 without additional funding.
• Proposed Merger: On July 14, 2026 (subsequent to the period end), the company entered into a Merger Agreement with an affiliate of its largest stockholder, Celadon Partners. The transaction involves a spin-off of the core business (including SENTI-202) into a private entity. Public shareholders would receive Contingent Value Rights (CVRs) with a potential aggregate payout of up to $60.0 million based on regulatory and sales milestones for SENTI-202.
• Post-Merger Strategy: If the merger closes, the public company will retain only early-stage programs (Rett Syndrome and TIL therapies) and will require significant additional capital to continue operations.
• Convertible Notes Risk: The $10.0 million in convertible notes mature on November 23, 2026. If not converted, the company must repay 200% of the principal ($20.0 million). Failure to repay could trigger default and foreclosure on company assets.
• Nasdaq Compliance: The company's stockholders' equity has fallen below the $2.5 million minimum requirement, and the market value of listed securities is below the $35 million threshold, creating a risk of delisting.

Investor Verification Checklist

• Merger Approval: Verify the status of the stockholder vote required to approve the Merger Agreement and the issuance of shares underlying the convertible notes.
• Liquidity Runway: Confirm the timeline for the remaining $2.0 million of "Additional Notes" funding from Celadon and the company's ability to raise capital post-merger.
• Debt Maturity: Assess the risk of the November 2026 maturity of the convertible notes and the likelihood of conversion versus cash repayment.
• Nasdaq Status: Monitor communications regarding the company's plan to regain compliance with Nasdaq listing standards (minimum equity and market value).
• CVR Milestones: Review the specific regulatory and sales milestones required to trigger the $60.0 million contingent value rights for shareholders.